BioXcel Therapeutics, Inc.
BTAIDrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
BXCL501
Agitation,Psychomotor
Sublingual film containing dexmedetomidine (BXCL501)
Agitation
BXCL501 Sublingual Film
Bipolar I Disorder
BXCL701 plus Pembrolizumab
Prostate Cancer
Dexmedetomidine
Opioid Withdrawal
Sublingual film containing Dexmedetomidine
Agitation,Psychomotor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BXCL501 | Phase 3 | Agitation,Psychomotor | - | - |
Sublingual film containing dexmedetomidine (BXCL501) | Phase 3 | Agitation | - | - |
BXCL501 Sublingual Film | Phase 2 | Bipolar I Disorder | - | - |
BXCL701 plus Pembrolizumab | Phase 2 | Prostate Cancer | - | - |
Dexmedetomidine | Phase 2 | Opioid Withdrawal | - | - |
Sublingual film containing Dexmedetomidine | Phase 2 | Agitation,Psychomotor | - | - |
Agitation,Psychomotor
2 drugs in this indication
Agitation
2 drugs in this indication
Bipolar I Disorder
1 drug in this indication
Prostate Cancer
1 drug in this indication
Opioid Withdrawal
1 drug in this indication
Agitation Associated With Bipolar Disorder
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)